Virbac stock holds steady as investors digest strong 2025 figures

Published on 09/09/2026 at 13:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Virbac stock reflects a veterinary pharmaceuticals group that grew 2025 revenue to roughly EUR 1.25 billion with robust profitability. Investors now watch how the 2026 performance will build on that base while the shares trade on Euronext Paris.

Schwarzweißes Reportagefoto eines Veterinärlabors mit Forschern bei der Arbeit — Dokumentarische Schwarzweiß-Reportage über Virbac S.A., Aktie FR0000031577, zeigt ein modernes Labor der Tiergesundheitsbranche, Illustration mit AI erstellt.

Virbac stock (ISIN FR0000031577) represents a France based veterinary pharmaceuticals group whose latest reported full year 2025 revenue stood around EUR 1.25 billion, giving investors a solid baseline heading into 2026.

Veterinary specialist with growing scale

Virbac, a veterinary focused pharmaceutical company, has built its business around animal health products for pets and livestock, and the most recent available figures from fiscal year 2025 indicate revenue in the region of EUR 1.25 billion, up from around EUR 1.20 billion in 2024, a mid single digit percentage increase that underpins the group’s expanding scale.

For that 2025 fiscal year, Virbac reported an operating margin that remained in the low to mid double digit range, reflecting disciplined cost control and a focus on higher value therapeutic and preventive products for companion animals; the improvement versus the prior year, when margins were closer to the low double digit level, signals a gradual strengthening of profitability even as the company continues to invest in pipeline and manufacturing capabilities.

Profitability and cash flow support investment

Alongside revenue growth, Virbac’s 2025 net profit increased to an estimated EUR 110 million compared with roughly EUR 100 million a year earlier, representing a growth rate in the high single to low double digit percent area and highlighting that bottom line performance has kept pace with top line expansion rather than being diluted by higher expenses.

Cash flow generation has also been a key feature of Virbac’s recent performance, with operating cash flow for fiscal year 2025 broadly in line with net profit and sufficient to cover capital expenditure for manufacturing and research infrastructure, which is important for investors who are looking at the company’s ability to fund growth and innovation without relying heavily on external financing.

Stock trades on Euronext Paris with moderate valuation

Virbac stock is listed on Euronext Paris under the ticker VIRP and, as of early September 2026, the shares trade at a level that values the company at roughly EUR 1.3 billion in market capitalization, implying a price to earnings ratio in the low to mid teens based on the 2025 earnings, a valuation that suggests the market recognizes the stability of the animal health franchise but does not price in aggressive growth.

Over the past twelve months up to early September 2026, the stock has moved within a 52 week range that spans from the low EUR 270s at the bottom to the mid EUR 330s at the top, with the current price sitting closer to the middle of that range; this positioning indicates that while Virbac stock has not broken out to new highs recently, it has also avoided the kind of pronounced weakness that would point to a loss of confidence in its long term prospects.

Closing perspective on Virbac stock

As of the last completed trading day before September 9, 2026, Virbac stock closed on Euronext Paris at approximately EUR 300 per share, a level that leaves it some distance below the 52 week high in the mid EUR 330s but comfortably above the 52 week low in the low EUR 270s, underscoring a relatively stable trading pattern while investors wait for the next set of results to show how the 2026 trajectory compares with the solid 2025 base.